Theravance Biopharma (NASDAQ:TBPH) Rating Lowered to Market Perform at SVB Leerink

Theravance Biopharma (NASDAQ:TBPH) was downgraded by equities researchers at SVB Leerink from an “outperform” rating to a “market perform” rating in a report issued on Tuesday, Marketbeat reports. They presently have a $10.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $15.00. SVB Leerink’s target price suggests a potential upside of 27.71% from the company’s current price.

A number of other research analysts have also weighed in on TBPH. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, May 29th. Finally, BTIG Research began coverage on Theravance Biopharma in a research report on Friday, April 12th. They issued a “buy” rating and a $21.00 price target for the company. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Theravance Biopharma has a consensus rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $7.83 on Tuesday. Theravance Biopharma has a 12 month low of $7.69 and a 12 month high of $11.71. The stock has a market capitalization of $380.80 million, a price-to-earnings ratio of -9.10 and a beta of 0.24. The firm has a fifty day simple moving average of $9.05 and a two-hundred day simple moving average of $9.09.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative net margin of 72.79% and a negative return on equity of 18.97%. The firm had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. During the same period in the previous year, the firm earned ($0.28) earnings per share. Equities analysts predict that Theravance Biopharma will post -0.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Several large investors have recently modified their holdings of the stock. Gerber LLC purchased a new position in Theravance Biopharma in the fourth quarter valued at approximately $112,000. Wellington Management Group LLP grew its stake in shares of Theravance Biopharma by 68.0% during the 4th quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock worth $3,227,000 after acquiring an additional 116,164 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Theravance Biopharma by 16.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock worth $474,000 after acquiring an additional 7,509 shares during the period. Bleakley Financial Group LLC purchased a new stake in Theravance Biopharma in the 4th quarter worth about $141,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Theravance Biopharma by 31.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 2,227 shares during the period. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.